Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs (original) (raw)

Nature volume 432, pages 173–178 (2004)Cite this article

Abstract

RNA interference (RNAi) holds considerable promise as a therapeutic approach to silence disease-causing genes, particularly those that encode so-called ‘non-druggable’ targets that are not amenable to conventional therapeutics such as small molecules, proteins, or monoclonal antibodies. The main obstacle to achieving in vivo gene silencing by RNAi technologies is delivery. Here we show that chemically modified short interfering RNAs (siRNAs) can silence an endogenous gene encoding apolipoprotein B (apoB) after intravenous injection in mice. Administration of chemically modified siRNAs resulted in silencing of the apoB messenger RNA in liver and jejunum, decreased plasma levels of apoB protein, and reduced total cholesterol. We also show that these siRNAs can silence human apoB in a transgenic mouse model. In our in vivo study, the mechanism of action for the siRNAs was proven to occur through RNAi-mediated mRNA degradation, and we determined that cleavage of the apoB mRNA occurred specifically at the predicted site. These findings demonstrate the therapeutic potential of siRNAs for the treatment of disease.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Novina, C. D. & Sharp, P. A. The RNAi revolution. Nature 430, 161–164 (2004)
    Article ADS CAS Google Scholar
  2. Scherr, M., Battmer, K., Dallmann, I., Ganser, A. & Eder, M. Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model. Oligonucleotides 13, 353–363 (2003)
    Article CAS Google Scholar
  3. Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Med. 9, 347–351 (2003)
    Article CAS Google Scholar
  4. Reich, S. J. et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210–216 (2003)
    CAS Google Scholar
  5. Zhang, X. et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J. Biol. Chem. 279, 10677–10684 (2004)
    Article CAS Google Scholar
  6. Dorn, G. et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32, e49 (2004)
    Article Google Scholar
  7. Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.-P. & Unverzagt, C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14, 4975–4977 (2004)
    Article CAS Google Scholar
  8. Burnett, J. R. & Barrett, P. H. Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. Crit. Rev. Clin. Lab. Sci. 39, 89–137 (2002)
    Article CAS Google Scholar
  9. Farese, R. V. Jr, Ruland, S. L., Flynn, L. M., Stokowski, R. P. & Young, S. G. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc. Natl Acad. Sci. USA 92, 1774–1778 (1995)
    Article ADS CAS Google Scholar
  10. Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986)
    Article ADS CAS Google Scholar
  11. Glueck, C. J. et al. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I. Metabolism 46, 625–633 (1997)
    Article CAS Google Scholar
  12. Enjoji, M., Wang, F., Nakamuta, M., Chan, L. & Teng, B. B. Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model. Hum. Gene Ther. 11, 2415–2430 (2000)
    Article CAS Google Scholar
  13. Linton, M. F. et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92, 3029–3037 (1993)
    Article CAS Google Scholar
  14. Purcell-Huynh, D. A. et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 95, 2246–2257 (1995)
    Article CAS Google Scholar
  15. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol. 21, 635–637 (2003)
    Article CAS Google Scholar
  16. Bridge, A. J., Pebernard, S., Ducraux, A., Nicoulaz, A.-L. & Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nature Genet. 34, 263–264 (2003)
    Article CAS Google Scholar
  17. Llave, C., Xie, Z., Kasschau, K. D. & Carrington, J. C. Cleavage of Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 20, 2053–2056 (2002)
    Article ADS Google Scholar
  18. Yekta, S., Shih, I. H. & Bartel, D. P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594–596 (2004)
    Article ADS CAS Google Scholar
  19. Damha, M. J. & Ogilvie, K. K. Oligoribonucleotide synthesis. The silyl-phosphoramidite method. Methods Mol. Biol. 20, 81–114 (1993)
    CAS PubMed Google Scholar
  20. Iyer, R. P., Egan, W., Regan, J. B. & Beaucage, S. L. 3H–1,2-benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid phase synthesis of oligodeoxyribonucleoside phosphorothioates. J. Am. Chem. Soc. 112, 1253–1254 (1990)
    Article CAS Google Scholar
  21. Zlot, C. H. et al. Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice. J. Lipid Res. 40, 76–84 (1999)
    CAS PubMed Google Scholar
  22. Hammad, S. M. et al. Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Metabolism 52, 916–921 (2003)
    Article CAS Google Scholar

Download references

Acknowledgements

We thank P. Sharp for his advice and creative input. We are grateful to J. Maraganore and T. Ulich for their support and encouragement. We would like to thank S. Young for the LF3 anti-mouse apoB antibody; D. Bartel and S. Yekta for advice on the 5′-RACE assay; S. Young and M. Stoffel for valuable discussions; and LipoFIT Analytic GmbH and the Institute for Biophysics and Physical Biochemistry of the University of Regensburg for the characterization of lipoprotein particles by NMR. For technical assistance we thank P. Deuerling, F. Hertel, S. Leuschner, N. Linke, A. Müller, G. Ott, H. Schübel, S. Shanmugam, M. Duckman and C. Auger.

Author information

Authors and Affiliations

  1. Alnylam Europe AG, Fritz-Hornschuch-Str. 9, 95326, Kulmbach, Germany
    Jürgen Soutschek, Birgit Bramlage, Rainer Constien, Anke Geick, Philipp Hadwiger, Matthias John, Ingo Röhl, Silvio Wuschko, Stefan Limmer & Hans-Peter Vornlocher
  2. Alnylam Pharmaceuticals Inc., 300 3rd Street, Cambridge, Massachusetts, 02142, USA
    Akin Akinc, Klaus Charisse, Mary Donoghue, Sayda Elbashir, Jens Harborth, Venkitasamy Kesavan, Gary Lavine, Rajendra K. Pandey, Timothy Racie, Kallanthottathil G. Rajeev, Ivanka Toudjarska, Gang Wang, David Bumcrot, Victor Koteliansky & Muthiah Manoharan

Authors

  1. Jürgen Soutschek
    You can also search for this author inPubMed Google Scholar
  2. Akin Akinc
    You can also search for this author inPubMed Google Scholar
  3. Birgit Bramlage
    You can also search for this author inPubMed Google Scholar
  4. Klaus Charisse
    You can also search for this author inPubMed Google Scholar
  5. Rainer Constien
    You can also search for this author inPubMed Google Scholar
  6. Mary Donoghue
    You can also search for this author inPubMed Google Scholar
  7. Sayda Elbashir
    You can also search for this author inPubMed Google Scholar
  8. Anke Geick
    You can also search for this author inPubMed Google Scholar
  9. Philipp Hadwiger
    You can also search for this author inPubMed Google Scholar
  10. Jens Harborth
    You can also search for this author inPubMed Google Scholar
  11. Matthias John
    You can also search for this author inPubMed Google Scholar
  12. Venkitasamy Kesavan
    You can also search for this author inPubMed Google Scholar
  13. Gary Lavine
    You can also search for this author inPubMed Google Scholar
  14. Rajendra K. Pandey
    You can also search for this author inPubMed Google Scholar
  15. Timothy Racie
    You can also search for this author inPubMed Google Scholar
  16. Kallanthottathil G. Rajeev
    You can also search for this author inPubMed Google Scholar
  17. Ingo Röhl
    You can also search for this author inPubMed Google Scholar
  18. Ivanka Toudjarska
    You can also search for this author inPubMed Google Scholar
  19. Gang Wang
    You can also search for this author inPubMed Google Scholar
  20. Silvio Wuschko
    You can also search for this author inPubMed Google Scholar
  21. David Bumcrot
    You can also search for this author inPubMed Google Scholar
  22. Victor Koteliansky
    You can also search for this author inPubMed Google Scholar
  23. Stefan Limmer
    You can also search for this author inPubMed Google Scholar
  24. Muthiah Manoharan
    You can also search for this author inPubMed Google Scholar
  25. Hans-Peter Vornlocher
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toJürgen Soutschek.

Ethics declarations

Competing interests

All authors are employees of Alnylam.

Supplementary information

Supplemental Figure 1

Specificity of apoB mRNA reduction in wild-type mice. siRNA-mediated reduction of apoB mRNA in liver mRNA pools from wild-type mice that received saline (_n_=10), Chol-mismatch-siRNA (_n_=10), and Chol-apoB-1-siRNA (_n_=10). The apoB mRNA was normalized to 4 reference mRNAs: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), glucose-6-phosphatase (G-6-P), factor VII (FVII) and vascular endothelial growth factor (VEGF). Data represent the mean of three independent measurements. Error bars illustrate the standard deviation of the mean. (JPG 18 kb)

Rights and permissions

About this article

Cite this article

Soutschek, J., Akinc, A., Bramlage, B. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.Nature 432, 173–178 (2004). https://doi.org/10.1038/nature03121

Download citation

This article is cited by

Associated content